Trial Profile
A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms PRADO
- Sponsors Sanofi
- 19 Jan 2022 This trial has been completed in Greece (End Date: 04 Feb 2009), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial is completed in france (Global End Date: 2009-02-04), according to European Clinical Trials Database record.
- 27 Jul 2020 This trial is completed in UK (Global End Date: 24 Oct 2008), according to European Clinical Trials Database record.